Zevra Therapeutics is a specialty pharmaceutical company focused on the discovery and development of treatments for central nervous system and rare disease indications that allow it to target areas with unmet needs. Co.'s prodrug product candidate pipeline is focused on the idiopathic hypersomnia (IH) and other CNS/rare diseases. Co.'s approved product, AZSTARYS®, a once-daily treatment for attention deficit hyperactivity disorder in patients, age six years and older, contains its prodrug, serdexmethylphenidate (SDX). Co.'s primary clinical development product candidate, KP1077, is based on SDX, its prodrug of d-methlyphenidate and is in development for the treatment of IH and narcolepsy. The ZVRA YTD return is shown above.
The YTD Return on the ZVRA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ZVRA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ZVRA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|